

## **Selbst-Monitoring der Blutglukose – Richtlinien für die Schweiz**

### **Empfehlungen der Schweizerischen Gesellschaft für Endokrinologie und Diabetologie (SGED)**

### **Auto-surveillance glycémique – directives pour la Suisse**

### **Recommandations de la Société Suisse d'Endocrinologie et de Diabétologie (SSED)**

#### **Literatur / Références**

1. Abbraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. *Diabetes Care*. 1995;18(8):1113–23.
2. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2007;28(1):88–136.
3. Schnell O, Alawi H, Battelino T, Ceriello A, Diem P, Felton A, et al. Addressing schemes of self-monitoring of blood glucose in type 2 diabetes: a European perspective and expert recommendation. *Diabetes Technol Ther*. 2011;13(9):959–65.
4. Allemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. *Curr Med Res Opin*. 2009;25(12):2903–13.
5. IQWiG. [https://www.iqwig.de/download/A05-08\\_Abschlussbericht\\_Zuckerselbstmessung\\_bei\\_Diabetes\\_mellitus\\_Typ\\_2.pdf](https://www.iqwig.de/download/A05-08_Abschlussbericht_Zuckerselbstmessung_bei_Diabetes_mellitus_Typ_2.pdf).
6. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. *Diabetes Care*. 2006;29(11):2433–8.
7. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB, Jr., Ferrara A, Liu J, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. *Am J Med*. 2001;111(1):1–9.
8. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. *Ann Intern Med*. 2006;144(7):465–74.
9. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. *Diabetes Care*. 2000;23(6):754–8.
10. Pollock RF, Valentine WJ, Goodall G, Brandle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. *Swiss Med Wkly*. 2010;140:w13103.
11. Schnell O AH, Battelino T, Ceriello A, Diem P, Felton A, Grzeszczak W, Harno K, Kempler P, Satman I, Vergès B. Consensus statement on self-monitoring of blood glucose in diabetes: A European perspective. *Diab Metabol Heart*. 2009;18:285–9.
12. Peel E, Parry O, Douglas M, Lawton J. Blood glucose self-monitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients' perspectives. *Br J Gen Pract*. 2004;54(500):183–8.
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):837–53.
14. Rizzo MR, Marfella R, Barbieri M, Boccardi V, Vestini F, Lettieri B, et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. *Diabetes Care*. 2010;33(10):2169–74.

15. Buscemi S, Re A, Batsis JA, Arnone M, Mattina A, Cerasola G, et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes. *Diabet Med.* 2010;27(8):872–8.
16. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA.* 2006;295(14):1681–7.
17. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. *Diabetes Obes Metab.* 2010;12(4):288–98.
18. Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, et al. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. *Diabetes Res Clin Pract.* 2007;77(3):420–6.
19. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. *Cochrane Database Syst Rev.* 2005(2):CD005060.
20. Hirsch IB, Bode BW, Childs BP, Close KL, Fisher WA, Gavin JR, et al. Self-Monitoring of Blood Glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research. *Diabetes Technol Ther.* 2008;10(6):419–39.
21. Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. *Diabetes Care.* 2011;34(2):262–7.
22. Duran A, Martin P, Runkle I, Perez N, Abad R, Fernandez M, et al. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. *J Diabetes.* 2010;2(3):203–11.
23. IDF. Guideline Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes. Available at: <http://www.idf.org/guidelines/self-monitoring>. 2009.
24. IDF. International Diabetes Federation: Global guideline for type 2 diabetes. Available at: <http://www.idf.org/guidelines/type-2-diabetes> 2005.
25. IDF: Guideline for Management of PostMeal Glucose in Diabetes 2011; available at: <http://www.idf.org>.
26. Matthaei S, Bierwirth R, Fritsche A, Gallwitz B, Häring HU, Joost HG, et al. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. *Diabetologie.* 2009;32–64.
27. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med.* 1993;329(14):977–86.
28. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. *Arch Ophthalmol.* 2008;126(12):1707–15.
29. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005;353(25):2643–53.
30. de Boer IH, Kestenbaum B, Rue TC, Steffes MW, Cleary PA, Molitch ME, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. *Arch Intern Med.* 2008;168(17):1867–73.
31. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, et al. The effect of intensive glycaemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes.* 2006;55(12):3556–65.
32. Matthaei S, Kellerer M. S3–Leitlinie Therapie des Typ-1–Diabetes. [http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte\\_Leitlinien/AktualisierungTherapieTyp1Diabetes\\_1\\_20120319\\_TL.pdf](http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/AktualisierungTherapieTyp1Diabetes_1_20120319_TL.pdf). 2011.
33. <http://www.bag.admin.ch/themen/krankenversicherung/00263/00264/04184/index.html>.
34. Gabrieli I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. *Cleve Clin J Med.* 2004;71(4):335–42.
35. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology, and management. *Clin Diabetes.* 2006;24:115–21.
36. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med.* 2007;147(6):386–99.
37. Kleinwechter H, Bühner C, Hösl I, Kainer F, Kautzky-Willer A, Pawlowski B, et al. Diabetes und Schwangerschaft. Aktualisierte Praxisempfehlungen der Deutschen Diabetes-Gesellschaft *Diabetologie.* 2011;6(Suppl 2):S191–S7.
38. Martin S, Buchholz G, Fach E, Jecht M, Kolb H, Landgraf R, et al. Rolle der Selbstmessung der Blutglukose (SMBG) bei Diabetes mellitus. Empfehlungen für eine individualisierte Messfrequenz. *Diabetologie.* 2009;5:460–70.